Support of existing NHSBT Low Density Lipid (LDL) Removal Apheresis

The Therapeutic Apheresis Services (TAS) function operates within the Clinical Services directorate of NHSBT. Multi-disciplinary TAS teams operate from eight regional hub units and three 3 spoke sites that are based within Acute NHS Trusts across England and South Wales. Each unit provides a portfolio of therapeutic treatments to both adult and paediatric patients from across a range of clinical specialities. Treatments provided include: Extracorporeal Photopheresis (ECP), Peripheral Blood Stem Cell (PBSC) Collection, Therapeutic Plasma Exchange (PEX), Red Cell Exchange (RCE), Low Density Lipid (LDL) Removal, Platelet / White Cell Depletion and Lymphocyte Collection.

The requirement of this procurement is for the supply of consumables and maintenance of the existing ART Universal machines.

This Framework Agreement is for a period of 2 years with two 1-year options to extend. It is the intension of NHSBT to award a Framework Agreement for these requirements by August 2021. The following contracting authorities will be able to purchase against the Framework Agreement: any NHS Authority or Trust.